# HemaCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemacell

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.xuejibio.com/
- Total disclosed funding: $20M
- Latest round: Series B (Jun 2, 2026)
- Investors on record: 14

## About

Based in Suzhou, China and established in 2021, Suzhou Xueji Biotechnology Co., Ltd., trading as HemaCell, is a stem cell biomedical company that focuses on the research and development of blood platelet medical products. The company's founder Fangfang Zhu, graduated from Peking University, and she was Vice president of WI Harper Group. The founder team members graduated from Stanford University, Harvard University, Peking University, etc. As of 2022, the company has 121 patents and 342 employees. In May 2026, it raised over CNY 100 million in series B2 funding.
The company engaged in cell therapy and drug development based on stem cells to bring blood regeneration. Its products can be used to treat blood system-related diseases, cancer radiotherapy and chemotherapy, critical care medicine, and thrombocytopenia in infectious diseases. It is also committed to discovering drugs that regulate platelet activation or function inhibition, which are used for diseases related to thrombocytopenia and various thrombotic diseases such as atherosclerosis, coronary heart disease, and cerebral infarction.
The company generates revenue from cell therapy and related drug development.
The company will use the funding to develop clinical trials for multiple indications of its flagship product and to develop pipelines such as platelet injections to address issues like blood supply shortages and bloodborne diseases, and significantly reduce the adverse consequences of blood transfusions. This capital increase will also be used to develop novel platelet-derived drugs for age-related indications.

## Funding rounds

- Series B, Jun 2, 2026, $15M — CDH Investments, Shenzhen Capital Real Estate Fund, Weidu Capital, Hebei Industrial Investment
- Series B, Jan 1, 2026, $5.7M — Coastal Industry Investment
- Series B, Dec 26, 2025 — Yonghui Capital
- Series B, Jul 1, 2025 — CDH Baifu Capital, Qingdao Guoxin Venture, Weido Capital, Zbjl Capital, Leader Venture Capital
- Series A, Dec 19, 2023 — CDH Investments, Qingdao Guoxin Venture, Zbjl Capital, Leader Venture Capital, Youth Innovation Fund
- Angel, Oct 9, 2021 — Oriza Holdings, Weidu Capital, Zhongli Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Weidu Capital (https://capitalatlas.ai/funds/weidu-capital) — Angel, Series B
- Zhongli Capital — Angel
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A, Series B
- Qingdao Guoxin Venture — Series A, Series B
- Zbjl Capital (https://capitalatlas.ai/funds/zbjl-capital) — Series A, Series B
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A, Series B
- Youth Innovation Fund — Series A
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series B
- Weido Capital (https://capitalatlas.ai/funds/weido-capital) — Series B
- Yonghui Capital (https://capitalatlas.ai/funds/yonghui-capital) — Series B
- Coastal Industry Investment (https://capitalatlas.ai/funds/coastal-industry-investment) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Hebei Industrial Investment — Series B